Immune checkpoint inhibitors (ICIs), such as PD-1 inhibitors and CTLA-4 inhibitors, have emerged as promising therapeutic agents by enhancing the host’s immune response against MM (121, 122). The gene discussed is PDCD1; the disease is Miyoshi myopathy.